
TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative ...
Background Despite the wide range of available treatment options for patients with hormone receptor–positive/HER2-negative (HR+/HER2–) recurrent or metastatic breast cancer, optimal treatment after progression on CDK4/6 inhibitors (CDK4/6i) …